KIYATEC clinical study data shows test accurately predicts brain cancer patient response
Validated platform with clinically actionable results creates real possibilities to improve care for glioblastoma (GBM) and other high-grade glioma patients
2021-06-17
(Press-News.org) KIYATEC, Inc. announced today the publication of new peer-reviewed data that establishes clinically meaningful prediction of patient-specific responses to standard of care therapy, prior to treatment, in newly diagnosed glioblastoma (GBM) and other high-grade glioma (HGG) patients. The results, the interim data analysis of the company's 3D-PREDICT clinical study, were published June 16, 2021 in Neuro-Oncology Advances, an open access clinical journal.
A goal of the study, which continues to enroll, was for the test's prospective, patient-specific response prediction to achieve statistical significance for predictive accuracy. The 3D-PREDICT study met this goal early, at its interim data analysis, an achievement that is uncommon for innovations in oncology. For clinicians and payors, the publication establishes the successful analytical validation and early clinical validation of KIYATEC's 3D Predict™ Glioma assay.
The recent bipartisan resolution passed by the US Senate designating July 21, 2021 as Glioblastoma Awareness Day highlights the severity of this aggressive brain cancer. Fewer than 10% of patients survive longer than five years. Pharmaceutical and clinical efforts have only resulted in modest increases in overall survival since the disease was first described in the 1920s. Today, most newly diagnosed patients receive the same treatment regimen (radiation therapy and temozolomide), presenting an opportunity to improve care through shifting the paradigm toward individualized medicine for HGG treatment.
KIYATEC's test results accurately identified the patients as future temozolomide responders or future non-responders prior to the initiation of drug treatment. The future responder group had a statistically significant 6-month comparative increase in overall survival. Since test results are available only seven days after surgery, this creates an opportunity to improve outcomes for each predicted non-responder by providing the possibility of patient-specific treatment strategies. In the future, KIYATEC's results may also prove useful to improve outcomes for each predicted responder through patient-specific combination strategies.
Successful response-prediction for newly diagnosed patients follows the company's previous success with predicting treatment response in recurrent high-grade glioma patients. In December 2020, KIYATEC announced a clinical case series demonstrating that use of their test doubled these patients' median time to progression over what would be expected without use of the test. In addition, the earlier announcement demonstrated successful clinical use of the targeted agent dabrafenib in two patients that were not identified by genetic sequencing. By identifying successful response to drugs that would have been missed by today's testing, KIYATEC's results expanded the successful treatment options for these patients.
"Decision making in our framework is based on patient-specific evidence, embodying truly personalized medicine. Evidence of response before the first dose is administered creates options that were not previously available when it comes to treatment," said Matthew Gevaert, PhD, CEO of KIYATEC.
Versus other approaches, tests developed using KIYATEC's 3D ex vivo cell culture platform demonstrate increased biological fidelity, which was first reported in 2019 in ovarian cancer. In newly diagnosed ovarian cancer patients, KIYATEC's test prospectively and accurately predicted response to first-line chemotherapy with 89% accuracy. The new GBM results now establish comparable predictive accuracy in two solid tumors, with eight additional cancers in the company's pipeline.
INFORMATION:
About KIYATEC
KIYATEC leverages its proprietary ex vivo 3D cell culture platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The platforms are positioned to address the gap-defining limitations of current cancer drug selection. The company's Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. The company's Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types.
Contact
KIYATEC, Inc.
Communications@kiyatec.com
MacDougall Advisors
Lauren Arnold, 781-235-3060
larnold@macbiocom.com
ELSE PRESS RELEASES FROM THIS DATE:
2021-06-17
Researchers from Bentley University, in partnership with Waltham Council on Aging in Massachusetts, and as part of a study funded by the National Science Foundation, have been exploring how the elderly use smart speakers at home. Waltham, a satellite city about eight miles west of Cambridge has a population of about 60,000, with about one in six being an elderly citizen. The purpose of the study was to understand how the elderly use the smart speaker technology at home. A smart speaker is a hardware device that is always-on. When a wake-word triggers the software contained in the device, the smart speaker listens to the command to provide a response or carry out the command (accessing resources ...
2021-06-17
When Ana K. Spalding, a Research Associate at the Smithsonian Tropical Research Institute (STRI) and Assistant Professor of Marine and Coastal Policy at Oregon State University (OSU) talks about mentorship in academia, she describes it as meaningful relationship. It goes beyond conversations about research and publications, and into shared experiences. This is just one approach--proposed by Spalding and 23 other women scientists from around the world, in a new article published in PLOS Biology--that calls for a shift in the value system of science to emphasize a more equal, diverse and inclusive academic culture.
The authors came together after reading a ...
2021-06-17
Superconductors are something like a miracle in the modern world. Their unique property of zero resistance can revolutionize power transmission and transport (e.g., Maglev train). However, most of the conventional superconductors require cooling down to extremely low temperatures that can only be achieved with liquid helium, a rather expensive coolant. Material scientists are now investigating "high-temperature superconductors" (HTSs) that can be cooled to a superconducting state by using the significantly cheaper liquid nitrogen (which has a remarkably higher temperature than liquid helium). ...
2021-06-17
TROY, N.Y. -- Optoelectronic materials that are capable of converting the energy of light into electricity, and electricity into light, have promising applications as light-emitting, energy-harvesting, and sensing technologies. However, devices made of these materials are often plagued by inefficiency, losing significant useful energy as heat. To break the current limits of efficiency, new principles of light-electricity conversion are needed.
For instance, many materials that exhibit efficient optoelectronic properties are constrained by inversion symmetry, a physical property that limits engineers' control of electrons in the material and their options for designing novel or efficient devices. In research published today in Nature ...
2021-06-17
With sorghum poised to become an important crop grown by Pennsylvania farmers, Penn State researchers, in a new study, tested more than 150 germplasm lines of the plant for resistance to a fungus likely to hamper its production.
Sorghum, a close relative to corn, is valuable for yielding human food, animal feed and biofuels. Perhaps its most notable attribute is that the grain it produces is gluten free. Drought resistant and needing a smaller amount of nutrients than corn to thrive, sorghum seems to be a crop that would do well in the Keystone State's ...
2021-06-17
The article 'The RNA Atlas expands the catalog of human non-coding RNAs', published today in Nature Biotechnology, is the result of more than five years of hard work to further unravel the complexity of the human transcriptome. Never before such a comprehensive effort was undertaken to characterize all RNA-molecules in human cells and tissues.
RNAs in all shapes and sizes
Our transcriptome is - analogous to our genome - the sum of all RNA molecules that are transcribed from the DNA strands that make up our genome. However, there's no 1-on-1 relationship with the latter. Firstly, each cell and tissue hasve a unique transcriptomes, with varying RNA production and compositions, including tissue-specific RNAs. Secondly, ...
2021-06-17
Additive manufacturing offers an unprecedented level of design flexibility and expanded functionality, but the quality and process can drastically differ across production machines, according to Hui Yang, a professor of industrial engineering at Penn State. With applications in aerospace, health care and automotive industries with potential for mass customization, additive manufacturing needs quality management.
To address this concern, Yang and a team of researchers from Penn State, University of Nebraska--Lincoln and the National Institute of Standards and Technology (NIST) proposed the design, development and implementation of a new data-driven methodology for quality control in additive manufacturing. They published their work in the Proceedings ...
2021-06-17
CAMBRIDGE, MA--Geothermal energy systems have the potential to power the world and become the leading technology for reducing greenhouse gas emissions if we can drill down far enough into the Earth to access the conditions necessary for economic viability and release the heat beneath our feet. END ...
2021-06-17
SAN ANTONIO (June 17, 2021) -- Convalescent plasma therapy was associated with better survival in blood cancer patients hospitalized with COVID-19, especially in sicker patients. The findings by the COVID-19 and Cancer Consortium (CCC19) are newly published in the peer-reviewed journal JAMA Oncology.
The Mays Cancer Center, home to UT Health San Antonio MD Anderson, is part of the CCC19. The international consortium is composed of 124 medical centers and institutions in North and South America that conduct research to learn how COVID-19 affects cancer patients.
Dimpy Shah, MD, PhD, is an epidemiologist and assistant professor of population health sciences at The University of Texas Health ...
2021-06-17
Forest fires have crept higher up mountains over the past few decades, scorching areas previously too wet to burn, according to researchers from McGill University. As wildfires advance uphill, a staggering 11% of all Western U.S. forests are now at risk.
"Climate change and drought conditions in the West are drying out high-elevation forests, making them particularly susceptible to blazes," says lead author Mohammad Reza Alizadeh, a PhD student at McGill University under the supervision of Professor Jan Adamowski. "This creates new dangers for mountain communities, with impacts on downstream water supplies and the plants and wildlife that call these forests home."
Climate warming has diminished 'flammability barrier'
In ...
LAST 30 PRESS RELEASES:
[Press-News.org] KIYATEC clinical study data shows test accurately predicts brain cancer patient response
Validated platform with clinically actionable results creates real possibilities to improve care for glioblastoma (GBM) and other high-grade glioma patients
